Quadruple wild‐type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways
MA Pantaleo, M Nannini, CL Corless… - Cancer …, 2015 - Wiley Online Library
MA Pantaleo, M Nannini, CL Corless, MC Heinrich
Cancer medicine, 2015•Wiley Online LibraryA subset of GIST s lack mutations in the KIT/PDGFRA or RAS pathways and yet retain an
intact succinate dehydrogensase (SDH) complex. We propose that these KIT/PDGFRA/SDH/
RAS‐P WT GIST tumors be designated as quadruple wild‐type (WT) GIST. Further
molecular and clinicophatological characterization of quadruple WT GIST will help to
determine their prognosis as well as assist in the optimization of medical management,
including clinical test of novel therapies.
intact succinate dehydrogensase (SDH) complex. We propose that these KIT/PDGFRA/SDH/
RAS‐P WT GIST tumors be designated as quadruple wild‐type (WT) GIST. Further
molecular and clinicophatological characterization of quadruple WT GIST will help to
determine their prognosis as well as assist in the optimization of medical management,
including clinical test of novel therapies.
Abstract
A subset of GISTs lack mutations in the KIT/PDGFRA or RAS pathways and yet retain an intact succinate dehydrogensase (SDH) complex. We propose that these KIT/PDGFRA/SDH/RAS‐P WT GIST tumors be designated as quadruple wild‐type (WT) GIST. Further molecular and clinicophatological characterization of quadruple WT GIST will help to determine their prognosis as well as assist in the optimization of medical management, including clinical test of novel therapies.
Wiley Online Library